Lindus Health co-founder Meri Beckwith named on PM360's 2025 Elite 100

The PM360 ELITE Awards, now in their tenth year, celebrate the top 100 visionaries across pharmaceutical, biotech and medical device industries whose leadership and innovation are driving real progress in patient care and drug development across 19 categories. Within the Drug Researchers and Developers category, PM360 spotlights the scientists, researchers, and clinical-trial experts who are delivering breakthrough, efficient treatment options for patients.

This year, our very own Meri Beckwith has been selected for 2025 ELITE 100 in recognition of building Lindus' tech-first, “anti-CRO” model that fully integrates proprietary in-house platforms with end-to-end services—streamlining trial workflows, cutting unnecessary overhead, and tackling entrenched inefficiencies in a $112 billion industry.

Meri’s selection reflects a career shaped by both investment and hands-on experience. After launching his professional journey as a venture capital investor partnering with digital health and biotech startups, he went on to participate in a diverse array of studies. His firsthand experience seeing operational bottlenecks, recruitment challenges and patient pain points directly inspired Lindus Health’s patient-centric approach and its mission to put study participants, not processes, at the core of every trial design.

Beyond his work at Lindus Health, Meri is a recognized thought leader—having delivered more than 20 presentations at major industry forums such as Wired Health and Amazon AI in Life Sciences—and he continues to shape the future of clinical research as an investor and board member across multiple healthtech and life sciences ventures. His ongoing exploration of generative AI, centralized real-time monitoring and other cutting-edge tools underscores Lindus Health’s commitment to faster, more reliable trials and lower costs for the healthcare system at large. A huge congratulations to Meri!

Click here to read his full profile.